Promising cocktail of drugs aims to wipe out esophageal tumors before surgery
NCT ID NCT07312578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced esophageal cancer. About 48 participants will be randomly assigned to receive the combination or standard chemo alone. The main goal is to see if the tumor disappears completely after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nimotuzumab, camrelizumab, albumin paclitaxel, and cisplatin
- What this could lead to
- If successful, this combination could shrink tumors more effectively before surgery, potentially improving long-term outcomes for patients with esophageal cancer.
- What could go wrong
- This is a small, early-phase trial with only 48 participants. The added drugs may increase side effects without guaranteeing better results, and the approach may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of GI Oncology, Peking University Cancer Hospital,
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads